Ryan J. Sullivan, MD, instructor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital (MGH), MGH Cancer Center, discusses findings from the ENCORE 601 trial in melanoma.
Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of medicine, Hematology/Oncology, Massachusetts General Hospital (MGH), MGH Cancer Center, discusses findings from the ENCORE 601 trial in melanoma.
In the phase Ib/II ENCORE 601 trial presented at the 2019 AACR Annual Meeting, investigators presented the interim results of the combination of the HDAC inhibitor entinostat and the anti—PD-1 inhibitor pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma who had progressed on or after prior anti–PD-1 therapy.
The combination was found to be effective and well tolerated, says Sullivan. Among the 53 evaluable patients in the melanoma cohort, 9 experienced a partial response to the combination and 1 patient experienced a complete response. Moreover, the responses appeared to be durable. At 1 year, 10 patients were free of disease progression.
Tissue and liquid biopsy were also suggestive of mechanistic changes as a result of the additive effects of entinostat, adds Sullivan.